LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

Company Overview

LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $8.27 to $8.64
• 50-Day Range: $7.81 to $8.80
• 52-Week Range: $6.40 to $9.14
• Volume: 13,435 shs
• Average Volume: 71,768 shs
• Market Capitalization: $392.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LOGC Stock Analysis - Frequently Asked Questions

How have LOGC shares performed this year?

LogicBio Therapeutics' stock was trading at $7.58 on January 1st, 2026. Since then, LOGC stock has increased by 13.5% and is now trading at $8.60.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) announced its quarterly earnings results on Friday, May, 9th. The company reported ($0.27) earnings per share (EPS) for the quarter.
Read the conference call transcript.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Compass Pathways (CMPS), Ginkgo Bioworks (DNA), Luminar Technologies (LAZR), Toast (TOST) and Globant (GLOB).

Company Calendar

• Last Earnings: 5/09/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Retail/Wholesale
• Industry: Catalog & mail - order houses
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:LOGC
• CIK: 1664106
• Web: www.logicbio.com
• Phone: (617) 245-0399
• Fax: N/A
• Employees: 62
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -20.68%
• Return on Assets: -13.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 31.14
• Quick Ratio: 31.14

Sales & Book Value

• Annual Sales: $43 million
• Price / Sales: 9.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.95 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 45,670,000
• Free Float: 45,450,000
• Market Cap: $392.76 million
• Optionable: No Data
• Beta: 2.10